Tetragenetics, Inc. is an early-stage biotechnology company meeting the needs of customers who seek a cost-effective alternative platform technology for the production of genetically engineered proteins. The company harnesses the unique biology of Tetrahymena thermophila. Tetragenetics’ technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express in conventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease. Tetragenetics is also actively pursuing an internal pipeline of hard-to-make proteins and monoclonal antibodies, in partnership with a number of biopharmaceutical companies.
A Cornell faculty member from the Department of Microbiology and Immunology in the College of Veterinary Medicine founded the company. It's foundational technology is licensed from Cornell University.